Schering-Plough Corporation 2001 Annual Report (Form 10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2001 for Schering-Plough Corporation, a global pharmaceutical holding company. The Company operates primarily in the prescription pharmaceutical marketplace, with significant portfolios in allergy/respiratory, anti-infective/anticancer, cardiovascular, and dermatological products. It also maintains businesses in animal health, foot care, over-the-counter (OTC), and sun care products. As of December 31, 2001, the Company employed approximately 29,800 people worldwide.
Key Financial Metrics
Revenue: Consolidated net sales for 2001 were $9,802 million, a flat performance compared to $9,815 million in 2000.
- Worldwide Pharmaceuticals: $8,369 million (flat vs. prior year).
- Animal Health: $694 million (down 4%).
- Foot Care, OTC, and Sun Care: Combined sales of $739 million (down 3%).
Profitability and Margins: The filing text does not provide specific values for net income, operating profit, or profit margins for the period. These figures are incorporated by reference from the 2001 Annual Report to Shareholders.
Cash Flow and Liquidity: Specific cash flow and liquidity metrics are not detailed in the provided text; they are incorporated by reference from the Annual Report.
Debt: Specific debt levels are not provided in the text.
Research and Development (R&D): R&D expenditures were $1,312 million in 2001, representing approximately 13% of consolidated net sales.
Material Changes vs. Prior Period
While total sales remained flat, significant shifts occurred within therapeutic categories:
- Anti-Infective & Anticancer: Sales increased 13% to $2,273 million, driven by a 49% increase in TEMODAR sales and significant growth in REMICADE.
- Allergy & Respiratory: Sales increased 1% to $4,217 million. Growth in CLARITIN/CLARINEX (5%) and NASONEX (26%) was offset by a 35% decline in VANCERIL and a 99% decline in VANCENASE.
- Cardiovasculars: Sales declined 17% to $623 million. While INTEGRILIN grew 34%, K-DUR, NITRO-DUR, and IMDUR saw declines of 26%, 18%, and 57% respectively.
- Dermatologicals: Sales declined 13% to $593 million, primarily due to a 55% drop in LOTRISONE sales.
Guidance, Outlook, Risks, and Contingencies
Patent Expirations and Generic Competition: The Company faces significant risk regarding the expiration of patents for CLARITIN (loratadine). The compound patent expires June 19, 2002, with market exclusivity extended to December 19, 2002. Management warns that the introduction of generic prescription or OTC loratadine would likely have a "rapid, sharp and material adverse effect" on results. The Company is litigating against 15 manufacturers seeking to market generic versions.
Regulatory and Manufacturing Issues: The FDA has cited deficiencies in Good Manufacturing Practices (GMPs) at facilities in New Jersey and Puerto Rico. The Company is negotiating a consent decree with the FDA, with a probable payment of $500 million.
Legal Proceedings:
- Antitrust and Pricing: The Company is subject to numerous investigations and lawsuits regarding Average Wholesale Price (AWP) reporting, Medicaid rebates, and alleged anti-competitive practices (including FTC proceedings regarding K-DUR settlements).
- Product Liability: The Company is a defendant in 225 lawsuits involving synthetic estrogens (DES) with claims exceeding $1.0 billion, though management deems material liability remote.
- Intellectual Property: Active litigation regarding patent infringement for CLARITIN, REBETOL, and PRIME PAC vaccine.
Outlook: The Company is pursuing the switch of CLARITIN to OTC status to extend its lifecycle, with FDA action targeted for November 28, 2002. New products awaiting approval include ZETIA, CLARINEX D, and ASMANEX.
Investor Verification Checklist
- Verify the final terms and financial impact of the FDA consent decree regarding GMP violations (estimated $500 million).
- Monitor the status of patent litigation concerning CLARITIN and the potential market entry of generic loratadine in late 2002.
- Review the full 2001 Annual Report to Shareholders for specific net income, cash flow, and debt figures not included in this text.
- Assess the progress of the FDA review for the CLARITIN OTC switch application.
- Track developments in government investigations regarding AWP reporting and Medicaid rebate calculations.